Raaj Medisafe India Ltd Upgraded to Buy on Strong Technical and Financial Performance

Technical Trends Turn Bullish, Driving Positive Momentum

The primary catalyst for the rating upgrade stems from a marked improvement in Raaj Medisafe’s technical profile. The technical grade shifted from mildly bullish to bullish, supported by a confluence of positive signals across multiple timeframes. Weekly and monthly MACD indicators both show bullish momentum, while Bollinger Bands confirm upward price volatility on weekly and monthly charts. Daily moving averages also remain bullish, reinforcing short-term strength.

Despite a weekly RSI reading that remains bearish, the overall technical picture is optimistic. The KST indicator is bullish on a weekly basis, though mildly bearish monthly readings and mixed Dow Theory signals suggest some caution. However, the On-Balance Volume (OBV) indicator is bullish across weekly and monthly periods, indicating strong buying interest. This technical backdrop supports the stock’s recent price appreciation, with the current price at ₹102.74, close to its 52-week high of ₹104.45.

Valuation Appears Attractive Amid Strong Returns

Raaj Medisafe’s valuation metrics further justify the upgrade. The company’s Return on Capital Employed (ROCE) stands at a respectable 9.9%, while the Enterprise Value to Capital Employed ratio is a low 2.2, signalling an attractive valuation relative to the capital invested. This valuation is particularly compelling given the stock’s market cap classification as a micro-cap, which often entails higher risk but also greater growth potential.

Despite a recent decline in profits by 66% over the past year, the stock has delivered impressive returns, outperforming benchmarks such as the BSE500 and Sensex. Over the last year, Raaj Medisafe generated a 36.99% return, significantly outpacing the Sensex’s negative 10.13% return. Longer-term returns are even more striking, with a 3-year return of 166.79% and a 10-year return exceeding 1,200%, underscoring the company’s capacity to deliver sustained shareholder value.

Robust Financial Trends Support Long-Term Growth Outlook

Raaj Medisafe’s financial performance in the recent quarter Q1 FY26-27 has been notably strong, reinforcing the upgrade decision. Net sales surged by 86.10% to ₹29.46 crores, while operating profit (PBDIT) reached a record ₹4.06 crores. The company’s cash and cash equivalents also hit a high of ₹13.01 crores in the half-year period, reflecting solid liquidity.

Over the longer term, the company has maintained healthy growth rates, with net sales expanding at an annualised rate of 33.80% and operating profits growing at 40.62%. These figures highlight the company’s ability to scale operations efficiently and improve profitability despite sector challenges.

However, investors should note that promoter holding has decreased this quarter to 59.08%, which may warrant monitoring for potential governance or strategic implications. Additionally, the company’s debt servicing capacity remains a concern, with a high Debt to EBITDA ratio of 5.45 times, indicating elevated leverage and potential financial risk.

Quality Assessment Reflects Market-Beating Performance

Raaj Medisafe’s overall quality grade has improved in line with its upgraded Mojo Score of 74.0, which corresponds to a Buy rating, up from the previous Hold grade. This score integrates multiple factors including financial health, valuation, and technical strength, providing a comprehensive view of the company’s investment merit.

The company’s market-beating returns over various time horizons further validate this quality upgrade. Notably, the stock has outperformed the Sensex and BSE500 indices over 1 year, 3 years, and 5 years, demonstrating consistent value creation for shareholders. This performance is particularly impressive given the company’s micro-cap status and the volatility often associated with smaller stocks.

Balancing Risks with Reward Potential

While the upgrade to Buy is supported by strong technicals, attractive valuation, and positive financial trends, investors should remain mindful of certain risks. The company’s high leverage, as indicated by the Debt to EBITDA ratio of 5.45 times, suggests limited ability to service debt comfortably. This could constrain financial flexibility, especially if operating conditions deteriorate.

Moreover, the recent decline in profits by 66% over the past year contrasts with the strong sales growth, signalling margin pressures or increased costs that require close monitoring. The decrease in promoter holding may also introduce some uncertainty regarding strategic direction or shareholder alignment.

Nonetheless, the company’s market-beating returns and improving technical indicators provide a compelling case for investors seeking exposure to the packaging sector’s growth potential through a micro-cap stock with demonstrated resilience and momentum.

Conclusion: Upgrade Reflects Comprehensive Improvement Across Key Parameters

The upgrade of Raaj Medisafe India Ltd’s investment rating to Buy by MarketsMOJO on 17 Sep 2026 is a reflection of a holistic improvement across four critical parameters: quality, valuation, financial trend, and technicals. The company’s technical indicators have turned decisively bullish, valuation metrics remain attractive relative to peers, financial performance shows robust growth in sales and operating profit, and overall quality scores have risen to support a positive outlook.

Investors should weigh these strengths against the risks posed by high leverage and profit volatility. However, the stock’s consistent outperformance of major indices and strong liquidity position provide a solid foundation for potential future gains. As such, Raaj Medisafe presents an intriguing opportunity for investors looking to capitalise on a micro-cap stock with improving fundamentals and technical momentum in the packaging sector.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →